Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharmatek Increases Liquid-Filling Capacity

By Drug Discovery Trends Editor | April 18, 2012

Pharmatek Laboratories Inc., a contract development and manufacturing organization (CDMO) supporting the pharmaceutical industry, announced that it has expanded its existing liquid encapsulation capabilities by purchasing a Qualicaps FS3 automated liquid filling and banding system. The addition of the Qualicaps FS3 unit to Pharmatek’s manufacturing capabilities increases overall efficiency at the Phase 2 production scale.

“The Qualicaps FS3 unit increases our scale of capsule filling, and it also has a number of other features that increase the quality of this particular dosage form,” stated Kevin Rosenthal, Director of Manufacturing for Pharmatek. “It has a robust gelatin band sealing technology that allows a quick visual check of seal integrity. The Qualicaps FS3 unit also has a heated hopper system for handling a broad range of liquid viscosities, including semi-solid and other BCS Class II formulations.”

The Qualicaps FS3 unit is equipped with an inert gas purge system and unique capsule lifting feature, allowing for the handling of oxygen sensitive drug products. The inert gas purge system presents warmed air, or inert gas, into the headspace of the capsule, minimizing process defects and thus increasing the overall product yield. The FS3 liquid filling and banding system is configured to handle clear or colored banding and gelatin or HPMC capsules ranging in sizes from 4 to 00.

“The acquisition of the Qualicaps FS3 unit increases our cGMP liquid capsule filling rate substantially. This increased rate allows Pharmatek to be more cost effective for larger scale liquid encapsulation projects. More efficient production of larger scale batches helps us to better support our clients through their late-stage Phase 2b clinical studies,” stated Jeffrey Bibbs, CEO and CSO of Pharmatek.

Date: April 16, 2012
Source: Pharmatek Laboratories Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE